CalciMedica, Inc. (CALC) Stock Score, Valuation & Financial Research
CalciMedica, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for CALC
CalciMedica, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.49. These figures are a research snapshot, not a buy or sell recommendation.
What CalciMedica, Inc. does
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
CalciMedica is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel calcium release-activated calcium (CRAC) channel inhibition therapies, relying on capital raises and potential future licensing or commercialization agreements to fund operations.
Products and services
- The company's primary product candidate is Auxora, a proprietary CRAC channel inhibitor being developed for the treatment of acute and chronic inflammatory and immunologic illnesses, including acute pancreatitis.
Brands and product families
- Auxora — Lead product candidate for the treatment of acute and chronic inflammatory and immunologic illnesses. Source
Customer types
Clinical trial participants.
Suppliers, materials and equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source
Business strengths to evaluate
- Proprietary CRAC channel inhibition technology platform Source
Business risks and research considerations
- History of operating losses and expectation of future losses Source
- Dependence on the success of a single lead product candidate, Auxora Source
- Need for additional capital to fund operations and clinical development Source
Sources: Company research source
Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
CALC financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 1.49
- Market capitalization:
- 4.69M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -21.24M
- Free cash flow:
- USD -21.21M
- Cash:
- USD 18.62M
- Total debt:
- USD 9.7M
- EPS:
- USD -6.90
What stands out
- Free cash flow is USD -21.21M, negative for the stored period.
- The balance sheet shows USD 18.62M of cash versus USD 9.7M of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 8.92M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for CALC
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can CALC fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is CALC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for CALC to reach sustainable profitability?
- What does the current corporate distress warning mean for the reliability or interpretation of CALC's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 64% of the scoring inputs required for this public page are currently available.
How to research CALC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.